Ofatumumab是一种全人源抗CD20单克隆抗体，它能够通过诱导抗体依赖性细胞介导的细胞毒性（ADCC）和补体依赖性细胞毒性（CDC），强力裂解表达CD20的B淋巴细胞。该药物对CD20阳性肿瘤细胞展现出强大的清除能力，并且对于CD20低表达的耐药细胞依然有效，在慢性淋巴细胞白血病（CLL）领域具有重要的研究价值。

Purity:SDS-PAGE

Anti-CD20 Reference Antibody (ofatumumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC

The purity of Anti-CD20 Reference Antibody (ofatumumab) is 100%, determined by SEC-HPLC.

Bioactivity:FACS

Romas cells were stained with Anti-CD20 Reference Antibody (ofatumumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.06641 ug/mL.

-25~-15℃保存，有效期1年。